FDA Warning Letter Explorer
Drugs · Letter issue date: May 29, 2025

Amish Origins Management, LLC

7 extracted findings · 5 model-assigned issue types

FDA source excerpt, selected passage

Your firm failed to conduct adequate release testing of all your drug products prior to distribution. Specifically, you did not test your drug products for identity, assay, impurities, or microbiological attributes.

Findings and supporting evidence

Model-assisted readings, not an exhaustive interpretation. Compare with the extracted source findings below.

Laboratory controls & testing21 CFR 211.165(a)

Failed to conduct adequate release testing for identity, assay, impurities, and microbiological attributes before distribution.

Supporting FDA text
Source excerpt · automated text-match check

Your firm failed to conduct adequate release testing of all your drug products prior to distribution. Specifically, you did not test your drug products for identity, assay, impurities, or microbiological attributes.

Components & suppliers21 CFR 211.84(d)(1)

Failed to perform identity testing on each component lot and failed to validate supplier test analyses.

Supporting FDA text
Source excerpt · automated text-match check

You failed to perform adequate identity testing of each component lot used in the manufacture of your OTC drug products, including for your active ingredient menthol and glycerin. Additionally, you relied on your suppliers’ certificates of analyses (COAs) without establishing the reliability of each of your suppliers’ test analyses at appropriate intervals.

Records & data integrity21 CFR 211.188

Failed to prepare batch production and control records with complete information for each batch.

Supporting FDA text
Source excerpt · automated text-match check

You failed to document the manufacturing instructions for your OTC drug products and did not have any executed batch records for distributed drug products.

Quality unit & oversight21 CFR 211.22

Quality control unit failed to exercise responsibility to ensure products comply with CGMP and meet specifications.

Supporting FDA text
Source excerpt · automated text-match check

Your quality unit (QU) did not effectively exercise its responsibilities to oversee the quality of your drug manufacturing operations. Specifically, you failed to have written procedures in place governing manufacturing and quality oversight.

Labeling, claims & marketing

External analgesic products are unapproved new drugs because they do not conform to the OTC monograph and lack approved applications.

Supporting FDA text
Source excerpt · automated text-match check

Your AMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Spray, AMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Ointment, AMISH ORIGINS AUTHENTIC DEEP PENETRATING Greaseless Pain Relief Cream, and AMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Aloe are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a) and 331(d).

Labeling, claims & marketing

External analgesic products are misbranded under section 502(ee) because they do not comply with OTC monograph requirements.

Supporting FDA text
Source excerpt · automated text-match check

AMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Spray, AMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Ointment, AMISH ORIGINS AUTHENTIC DEEP PENETRATING Greaseless Pain Relief Cream, and AMISH ORIGINS AUTHENTIC DEEP PENETRATING Pain Relief Aloe are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee), because these products are nonprescription drugs subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section and are not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355.

Labeling, claims & marketing

Sunscreen product is misbranded under section 502(f)(2) for lacking required warnings.

Supporting FDA text
Source excerpt · automated text-match check

Your AMISH ORIGINS AUTHENTIC LIP DOC SPF 15 MEDICATED product misbranded under section 502(f)(2) of the FD&C Act because its labeling does not “[bear]…such adequate warnings against use in those pathological conditions or by children where its use may be dangerous to health, or against unsafe dosage or methods or duration of administration or application, in such manner and form, as are necessary for the protection of users…”. Here, the warning described in the product labeling fails to bear all of the required warnings for sunscreen drug products described in M020.50(d)(1)(i) and (ii) “Over-the-Counter Monograph M020: Sunscreen Drug Products for Over-the-Counter Human Use”. Specifically, your product fails to disclose the required warnings, “Do not use on damaged or broken skin,” and “keep out of eyes.”

Labeling, claims & marketing

Sunscreen product is misbranded under section 502(ee) for not complying with OTC monograph requirements.

Supporting FDA text
Source excerpt · automated text-match check

your AMISH ORIGINS AUTHENTIC LIP DOC SPF 15 MEDICATED product is misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee), because this product is a nonprescription drugs subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but does not comply with the requirements for marketing under that section (as described above) and is not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355.

Findings extracted from the letter

Selected FDA passages, not the complete letter.

01
Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release, and for each batch of drug product required to be free of objectionable microorganisms, appropriate laboratory testing, as necessary (21 CFR 211.165(a) and 211.165(b)).
02
Your firm failed to conduct adequate release testing of all your drug products prior to distribution. Specifically, you did not test your drug products for identity, assay, impurities, or microbiological attributes.
03
Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).
04
You failed to perform adequate identity testing of each component lot used in the manufacture of your OTC drug products, including for your active ingredient menthol and glycerin. Additionally, you relied on your suppliers’ certificates of analyses (COAs) without establishing the reliability of each of your suppliers’ test analyses at appropriate intervals.
05
Your firm failed to prepare batch production and control records with complete information relating to the production and control of each batch of drug product produced (21 CFR 211.188).
06
You failed to document the manufacturing instructions for your OTC drug products and did not have any executed batch records for distributed drug products.
07
Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.

What FDA requested

Model-assisted summary. Consult the letter for complete requests and conditions.

  • A list of chemical and microbial specifications, including test methods, used to analyze each batch of your drug products before a batch disposition decision.
  • An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.
  • A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.
  • A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of glycerin, propylene glycol, and certain additional high-risk components we note that this includes the performance of parts A, B, and C of the USP monograph.
  • A commitment to provide DEG and EG test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product lots for the presence of DEG and EG.
  • A full risk assessment for drug products that are within expiry which contain any ingredient at risk for DEG or EG contamination (including, but not limited to, propylene glycol). Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain DEG or EG, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate CAPAs that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.
  • The chemical and microbiology quality control specifications you use to test each incoming lot of high-risk drug components to determine acceptability for use in manufacturing.
  • A comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.

Sections and clauses cited

As cited in this historical letter, not a statement of current regulatory requirements.

Keep exploring

More drug letters

Recent records for the same product type. Your previous filters remain available when you return.

Keep exploring

For regulated teams

Put this kind of reading to
work on your own records.

Botable builds and runs a custom AI layer around the software you already use, so your team can do the job you hired them for.

FDA Warning Letter Alerts

Share this view

Send the same filters, search and view to a colleague.

You choose what to post or send. Sharing a link does not change access to this site.